AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CHIMERIC THERAPEUTICS LTD

0.004

-0.001-20.00%

Volume:289.03K

Turnover:1.24K

Market Cap:6.48M

PE:-0.21

High:0.005

Open:0.005

Low:0.004

Close:0.005

Loading ...

Overview Company News Filings

Chimeric Therapeutics Ltd-Entitlement Offer Closing Date Extended to 22 April 2025

THOMSON REUTERS

Chimeric Therapeutics Secures US Patent Allowance for Gastrointestinal Cancer Therapy

MT Newswires Live

BRIEF-Chimeric Therapeutics Says US Patent Allowed For CHM CDH17 Technology

Chimeric Therapeutics Ltd-Entitlement Offer Documents

THOMSON REUTERS

BRIEF-Chimeric Therapeutics To Raise A$3.2 Million

Chimeric Therapeutics Ltd - Offer Price Set at a$0.005 per New Share

THOMSON REUTERS

Chimeric Therapeutics Ltd-Entitlement Offer to Raise Approximately $3.2 Million

THOMSON REUTERS

Chimeric Therapeutics - All Currencies in AUD

THOMSON REUTERS

Chimeric Therapeutics to Raise AU$3.2 Million via Entitlement Offer

MT Newswires Live

BUZZ-Australia's Chimeric Therapeutics falls on discounted placement

BRIEF-Chimeric Therapeutics To Raise Up To A$3.2 Mln At A$0.005 Per Share

Chimeric Therapeutics Ltd - to Raise up to a$3.2 Mln at a$0.005 per Share

THOMSON REUTERS

Chimeric Therapeutics Ltd-Proposed Issue of Securities - Chm

THOMSON REUTERS

Chimeric Therapeutics Receives AU$4 Million Funding to Develop Cancer Targeting Cell Therapy

MT Newswires Live

BRIEF-Chimeric Therapeutics Announces A$4.0 Million Non-Dilutionary Funding

Chimeric Therapeutics - US-Based Family Office Provides a$4.0 Mln Non-Dilutionary Funding for Development of Chm Cdh17 CAR-T

THOMSON REUTERS

BRIEF-Chimeric Therapeutics Seeks Trading Halt Pending Announcements In Relation To A Capital Raising, Non-Dilutionary Funding

Chimeric Therapeutics Ltd - Seeks Trading Halt Pending Announcements in Relation to a Capital Raising, Non-Dilutionary Funding

THOMSON REUTERS

Chimeric Therapeutics Says University of Chicago Joins CAR T-Cell Therapy Study for Gastrointestinal Cancers

MT Newswires Live

This Chimeric Therapeutics Insider Increased Their Holding By 97% Last Year

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CHM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CHM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","market":"AU","secType":"STK","nameCN":"CHIMERIC THERAPEUTICS LTD","latestPrice":0.004,"timestamp":1745302320000,"preClose":0.005,"halted":0,"volume":289032,"delay":0,"nameEN":"CHIMERIC THERAPEUTICS LTD","floatShares":1285276375,"shares":1620149846,"eps":-0.019396,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"04-22 16:12:00 AEST","open":0.005,"high":0.005,"low":0.004,"amount":1242,"amplitude":0.2,"askPrice":0.005,"askSize":1880000,"bidPrice":0.004,"bidSize":15727089,"shortable":3,"etf":0,"ttmEps":-0.019396,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.005,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":0.13518755829452694,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CHM.AU\",,,,,undefined,":{"symbol":"CHM.AU","floatShares":1285276375,"roa":"-48.71%","roe":"-180.09%","lyrEps":-0.018011,"volumeRatio":0.13518755829452694,"shares":1620149846,"dividePrice":0,"high":0.005,"amplitude":0.2,"preClose":0.005,"low":0.004,"week52Low":0.004,"pbRate":"1.09","psRate":"3.17","week52High":0.032,"institutionHeld":0,"latestPrice":0.004,"committee":0.78645,"eps":-0.019396,"divideRate":0,"volume":289032,"delay":0,"ttmEps":-0.019396,"open":0.005,"prevYearClose":0.007,"prevWeekClose":0.005,"prevMonthClose":0.005,"prevQuarterClose":0.005,"fiveDayClose":0.005,"twentyDayClose":0.005,"sixtyDayClose":0.006},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CHM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524444680","title":"Chimeric Therapeutics Ltd-Entitlement Offer Closing Date Extended to 22 April 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524444680","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524444680?lang=en_us&edition=fundamental","pubTime":"2025-04-03 05:25","pubTimestamp":1743629135,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nTUE1BFFMB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2522051059","title":"Chimeric Therapeutics Secures US Patent Allowance for Gastrointestinal Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2522051059","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522051059?lang=en_us&edition=fundamental","pubTime":"2025-03-25 11:25","pubTimestamp":1742873144,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics  secured a US patent allowance for its CHM CDH17 chimeric antigen receptor technology, a CAR-T therapy targeting gastrointestinal cancers, according to a Tuesday filing with the Australian bourse.The patent application is for compositions and methods for retrieving tumor-related antibodies and antigens, the filing said.The patent allowance is expected to provide patent protection until at least 2039.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","CHM.AU","BK7067"],"gpt_icon":0},{"id":"2522312035","title":"BRIEF-Chimeric Therapeutics Says US Patent Allowed For CHM CDH17 Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2522312035","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522312035?lang=en_us&edition=fundamental","pubTime":"2025-03-25 08:55","pubTimestamp":1742864131,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Says US Patent Allowed For CHM CDH17 TechnologyMarch 25 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:US PATENT ALLOWED FOR CHM CDH17 TECHNOLOGYFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q7183:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2522086715","title":"Chimeric Therapeutics Ltd-Entitlement Offer Documents","url":"https://stock-news.laohu8.com/highlight/detail?id=2522086715","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522086715?lang=en_us&edition=fundamental","pubTime":"2025-03-25 06:09","pubTimestamp":1742854157,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250324:nTUE3DSSWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2520636977","title":"BRIEF-Chimeric Therapeutics To Raise A$3.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520636977","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520636977?lang=en_us&edition=fundamental","pubTime":"2025-03-18 08:19","pubTimestamp":1742257177,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics To Raise A$3.2 MillionMarch 18 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:ENTITLEMENT OFFER TO RAISE APPROXIMATELY A$3.2 MILLIONOFFER PRICE SET AT A$0.005 PER NEW SHAREFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUE986F2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2520876646","title":"Chimeric Therapeutics Ltd - Offer Price Set at a$0.005 per New Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2520876646","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520876646?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:39","pubTimestamp":1742251167,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUE986F2Z:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2520692687","title":"Chimeric Therapeutics Ltd-Entitlement Offer to Raise Approximately $3.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2520692687","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520692687?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:39","pubTimestamp":1742251167,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUE986F2Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2520687669","title":"Chimeric Therapeutics - All Currencies in AUD","url":"https://stock-news.laohu8.com/highlight/detail?id=2520687669","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520687669?lang=en_us&edition=fundamental","pubTime":"2025-03-18 06:39","pubTimestamp":1742251167,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nTUE986F2Z:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2517899982","title":"Chimeric Therapeutics to Raise AU$3.2 Million via Entitlement Offer","url":"https://stock-news.laohu8.com/highlight/detail?id=2517899982","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517899982?lang=en_us&edition=fundamental","pubTime":"2025-03-05 06:09","pubTimestamp":1741126172,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics  said it intends to raise AU$3.2 million through a pro-rata, non-renounceable entitlement offer, according to a Tuesday filing with the Australian bourse.The offer, priced at AU$0.005 per share, will allow eligible shareholders to subscribe for two new shares for every five existing shares held and represents an over 23% discount to the stock's last closing price, the filing said.Investors will also receive one new option per share subscribed, exercisable at AU$0.008, expiring on Dec. 19, subject to shareholder approval, the filing added.Funds raised will support ongoing clinical trials, and shareholders will have the option to apply for additional shares beyond their entitlement, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7067","CHM.AU","LENZ"],"gpt_icon":0},{"id":"2516905416","title":"BUZZ-Australia's Chimeric Therapeutics falls on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516905416","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516905416?lang=en_us&edition=fundamental","pubTime":"2025-03-04 10:48","pubTimestamp":1741056500,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Chimeric Therapeutics falls on discounted placement** Chimeric Therapeutics CHM.AX falls 7.7% to A$0.006, lowest since February 26** Biotech firm says it intends to raise up to A$3.2 mln  at A$0.005, a discount of 28.6% to last close** Adds funds will used for continued development of co's CDH17 Phase 1/2 clinical trial** Stock down 14.3% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nL3N3PN0CL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2516696899","title":"BRIEF-Chimeric Therapeutics To Raise Up To A$3.2 Mln At A$0.005 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2516696899","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516696899?lang=en_us&edition=fundamental","pubTime":"2025-03-04 09:01","pubTimestamp":1741050108,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics To Raise Up To A$3.2 Mln At A$0.005 Per ShareMarch 4 (Reuters) - Chimeric Therapeutics Ltd CHM.AX:TO RAISE UP TO A$3.2 MILLION AT A$0.005 PER SHAREFurther company coverage: CHM.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM123:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2516225695","title":"Chimeric Therapeutics Ltd - to Raise up to a$3.2 Mln at a$0.005 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2516225695","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516225695?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:59","pubTimestamp":1741049992,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nFWN3PM123:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2516695229","title":"Chimeric Therapeutics Ltd-Proposed Issue of Securities - Chm","url":"https://stock-news.laohu8.com/highlight/detail?id=2516695229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516695229?lang=en_us&edition=fundamental","pubTime":"2025-03-04 08:59","pubTimestamp":1741049967,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250304:nTUE9RBNDX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2514909183","title":"Chimeric Therapeutics Receives AU$4 Million Funding to Develop Cancer Targeting Cell Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514909183","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514909183?lang=en_us&edition=fundamental","pubTime":"2025-02-28 14:49","pubTimestamp":1740725366,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics  has received AU$4 million in non-dilutionary funding to develop its CHM CDH17, a cell therapy targeting cancer, according to a Thursday filing with the Australian bourse.The funds, provided by an undisclosed US-based philanthropic family office, are non-refundable, with no further obligations, and no equity or intellectual property has been transferred, the filing said.Chimeric clarified that the identity of the philanthropic family office does not have any material impact on the company's securities, the filing added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","LENZ","BK4139","CHM.AU"],"gpt_icon":0},{"id":"2514402098","title":"BRIEF-Chimeric Therapeutics Announces A$4.0 Million Non-Dilutionary Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2514402098","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514402098?lang=en_us&edition=fundamental","pubTime":"2025-02-27 15:03","pubTimestamp":1740639817,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Announces A$4.0 Million Non-Dilutionary FundingFeb 27  - Chimeric Therapeutics Ltd CHM.AX:US-BASED FAMILY OFFICE PROVIDES A$4.0 MILLION NON-DILUTIONARY FUNDING FOR DEVELOPMENT OF CHM CDH17 CAR-TFurther company coverage: CHM.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CHM.AU","BK7067"],"gpt_icon":0},{"id":"2514846505","title":"Chimeric Therapeutics - US-Based Family Office Provides a$4.0 Mln Non-Dilutionary Funding for Development of Chm Cdh17 CAR-T","url":"https://stock-news.laohu8.com/highlight/detail?id=2514846505","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514846505?lang=en_us&edition=fundamental","pubTime":"2025-02-27 13:06","pubTimestamp":1740632803,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1WH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2514166848","title":"BRIEF-Chimeric Therapeutics Seeks Trading Halt Pending Announcements In Relation To A Capital Raising, Non-Dilutionary Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2514166848","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514166848?lang=en_us&edition=fundamental","pubTime":"2025-02-27 09:41","pubTimestamp":1740620478,"startTime":"0","endTime":"0","summary":"BRIEF-Chimeric Therapeutics Seeks Trading Halt Pending Announcements In Relation To A Capital Raising, Non-Dilutionary FundingFeb 27  - Chimeric Therapeutics Ltd CHM.AX:SEEKS TRADING HALT PENDING ANNOUNCEMENTS IN RELATION TO A CAPITAL RAISING, NON-DILUTIONARY FUNDINGFurther company coverage: CHM.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1VR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2514891684","title":"Chimeric Therapeutics Ltd -  Seeks Trading Halt Pending Announcements in Relation to a Capital Raising, Non-Dilutionary Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2514891684","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514891684?lang=en_us&edition=fundamental","pubTime":"2025-02-27 07:06","pubTimestamp":1740611181,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250226:nFWN3PH1VR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","CHM.AU"],"gpt_icon":0},{"id":"2510005130","title":"Chimeric Therapeutics Says University of Chicago Joins CAR T-Cell Therapy Study for Gastrointestinal Cancers","url":"https://stock-news.laohu8.com/highlight/detail?id=2510005130","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510005130?lang=en_us&edition=fundamental","pubTime":"2025-02-10 13:35","pubTimestamp":1739165757,"startTime":"0","endTime":"0","summary":"Chimeric Therapeutics  said that the University of Chicago Medicine will enroll patients in its multi-center phase one/two clinical trial for its anti-CDH17 chimeric antigen receptor T-cell therapy, according to a Monday Australian bourse filing.The trial is a two-stage study to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.CHM CDH17 is a CAR T-cell therapy, a type of immunotherapy, that targets CDH17, a cancer target associated with poor prognosis and metastases in the most common gastrointestinal tumors, the filing said.The first phase of the study is expected to enroll 15 patients.Its shares rose 14% on market close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CHM.AU","BK4230","CAR","LENZ","BK4022","BK7067","BK4139"],"gpt_icon":0},{"id":"2508510105","title":"This Chimeric Therapeutics Insider Increased Their Holding By 97% Last Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2508510105","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508510105?lang=en_us&edition=fundamental","pubTime":"2025-02-04 11:01","pubTimestamp":1738638079,"startTime":"0","endTime":"0","summary":"Looking at Chimeric Therapeutics Limited's  insider transactions over the last year, we can see that insiders were net buyers. That is, there were more number of shares purchased by insiders than there were sold.Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.Check out our latest analysis for Chimeric Therapeutics. The Last 12 Months Of Insider Transactions At Chimeric Therapeutics. The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest Chimeric Therapeutics insiders are well aligned, and that they may think the share price is too low. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Chime","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/chimeric-therapeutics-insider-increased-holding-030119170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK4139","BK7067","LENZ","CHM.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":29,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CHM.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CHM.AU\",market:\"AU\",,,undefined,":[]}}